A Randomized, Double-blind, Parallel-group, Multi-center Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety After Daily Oral Administration of 4 Different Doses of Vilaprisan (BAY1002670) in Healthy Women of Reproductive Age
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Vilaprisan (Primary)
- Indications Uterine leiomyoma
- Focus Pharmacodynamics
- Sponsors Bayer
- 12 Sep 2017 Results published in the Journal of Clinical Pharmacology
- 14 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 06 Nov 2015 Planned End Date changed from 1 Oct 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov.